Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Pulmonary Drug Delivery Devices Market Poised To Hit $71.9 Billion By 2030 With A 6.2% CAGR
The market size for pulmonary drug delivery devices has experienced substantial growth in recent years. The market is projected to expand from $52.8 billion in 2025 to $56.49 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this historical expansion include the increasing prevalence of respiratory diseases, a rising adoption of inhalation therapies, the expansion of asthma and COPD treatment programs, ongoing improvements in inhaler design technologies, and growing awareness regarding pulmonary drug delivery.
The pulmonary drug delivery devices market is set for robust expansion in the foreseeable future. It is anticipated to achieve a valuation of $71.9 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 6.2%. This growth during the projection period stems from factors such as increasing demand for personalized respiratory therapies, the growing uptake of digital health-integrated inhalers, the broadening scope of home-based respiratory care, an increased emphasis on non-invasive drug delivery, and continuous innovation in inhalation technologies. Significant trends for this period encompass the rising adoption of smart and connected inhaler devices, an escalating demand for targeted pulmonary drug delivery, the expanded utilization of mesh and ultrasonic nebulizers, the development of more combination drug-device products, and a stronger focus on patient adherence.
Get A Free Sample Report With In-Depth Market Insights:
Pulmonary Drug Delivery Devices Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing occurrence of respiratory conditions is anticipated to drive the expansion of the pulmonary drug delivery devices market in the future. These disorders encompass illnesses or states that impact the lungs and airways, thereby affecting a person’s breathing. The growing incidence of respiratory ailments stems from multiple causes, including elevated air pollution, higher smoking percentages, urbanization, changes in climate, and an older demographic. Crucially, pulmonary drug delivery devices are vital in managing respiratory disorders as they enable direct administration of medicines to the lungs. To illustrate, a research study featured in JAMA Network Open, a medical journal from the American Medical Association, indicated in December 2023 that the worldwide prevalence of chronic obstructive pulmonary disease (COPD) is projected to reach almost 600 million cases by 2050, representing a 23% rise in its occurrence. Consequently, this increasing prevalence of COPD is serving as a catalyst for the expansion of the pulmonary drug delivery devices market.
Pulmonary Drug Delivery Devices Market Segmentation: How Does The Market Break Down By Category?
The pulmonary drug delivery devices market covered in this report is segmented –
1) By Product Type: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers
2) By Application: Asthma, Cystic Fibrosis, Chronic Obstructive Pulmonary Disease, Other Applications
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, E-Commerce
Subsegments:
1) By Dry Powder Inhalers (DPIs): Single-Dose DPIs, Multi-Dose DPIs
2) By Metered Dose Inhalers (MDIs): CFC-Based MDIs, HFA-Based MDIs
3) By Nebulizers: Jet Nebulizers, Ultrasonic Nebulizers, Mesh Nebulizers
#Pulmonary Drug Delivery Devices Market Growth Trends: What’s Shaping The Future Outlook?
Major companies in the pulmonary drug delivery devices market are developing innovative products, such as small-volume nebulizers, to offer customers enhanced features. A small-volume nebulizer (SVN) is a medical apparatus used to administer liquid medication as an aerosolized mist to patients with respiratory ailments like asthma, chronic obstructive pulmonary disease (COPD), or cystic fibrosis. For instance, in May 2024, Medline Industries LP, a US-based healthcare company, launched the Hudson RCI TurboMist small-volume nebulizer. This pioneering device is designed to deliver medication treatments quickly, in as little as three minutes. The advanced nebulizer can dispense 2.5 times more medication per minute compared to standard nebulizers, reducing treatment times by about 70%. This increased medication delivery substantially shortens treatment durations, benefiting healthcare providers by optimizing patient throughput and enhancing the patient experience by shortening the duration of therapy sessions.
Pulmonary Drug Delivery Devices Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the pulmonary drug delivery devices market are Medtronic plc, Air Liquide S.A., Becton Dickinson And Company, Koninklijke Philips N.V., Medline Industries Inc., ResMed Inc., Drägerwerk AG And Co. KGaA, Smiths Group plc, AptarGroup Inc., Chiesi Farmaceutici S.p.A., Teleflex Incorporated, Fisher And Paykel Healthcare Limited, Invacare Corporation, Vyaire Medical Inc., Inogen Inc., Drive DeVilbiss Healthcare Inc., Hovione, Hamilton Medical AG, GaleMed Corporation, Allied Healthcare Products Inc., Precision Medical Inc., Salter Labs Inc.
View The Full Pulmonary Drug Delivery Devices Market Report:
Pulmonary Drug Delivery Devices Market Geographic Spread And Regional Opportunities
North America was the largest region in the pulmonary drug delivery devices market in 2025. The regions covered in the pulmonary drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
